It is possible that bleomycin is not able to induce typical type 2 immune response–mediated lung fibrosis, or that ILC2s contribute to fibrosis development through other pathways, including the EGFR pathway that was investigated above. This evidence concerns the gene EGFR and pulmonary fibrosis.